Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2013

View Archived Issues

Agilent Technologies partners with University of Queensland on oral cancer research

OraSure terminates assay collaboration with Roche Diagnostics

Single Cell Technology and AB Biosciences to identify therapeutic antibodies

GE Healthcare develops Affibody-based radiotracer to assess HER2 status

In vivo characterization of a potent mechanism-based therapeutic agent

Eisai joins tuberculosis drug accelerator partnership

Summit and the University of Oxford to develop treatments for DMD

E39 is well tolerated in patients with endometrial and ovarian cancer

Sanofi presents promising in vivo results for PDE-78INH

Achaogen discloses new agents for bacterial infections

AbbVie patents novel Nampt inhibitors for cancer and other disorders

EMA grants accelerated assessment to faldaprevir

Researchers in Luxembourg synthesize novel compound for infections

CleveXel and Dynamix to develop new treatment for rheumatoid arthritis

Bayer Schering Pharma discloses new chymase inhibitors

Takeda Pharmaceutical divulges new MCH1 receptor antagonists for obesity

VMY-2-109 treatment leads to reduction in nicotine self-administration in vivo

Nanovi secures funding to support development of BioXmark

FDA approves new delayed-release tablet formulation of posaconazole

Lytix Biopharma enrolls first patient in study of LTX-315

FDA accepts Targiniq ER NDA for review

Genmab reaches milestone in Janssen Biotech collaboration

Merrimack and Actavis form nanotechnology collaboration

QRxPharma refiles MoxDuo NDA

Novartis describes malate salts of diazaspiro ghrelin receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...